The Curium-Lantheus merger is worth up to $8bn. What does it say about the race to control radiopharmaceutical infrastructure?
Curium’s agreement to acquire Lantheus Holdings combines a major United States radiodiagnostics franchise with Curium’s global isotope, manufacturing and nuclear-medicine infrastructure. The strategic logic goes well beyond one imaging agent and points toward increasing value being placed on end-to-end radiopharmaceutical capabilities.